Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial - Aix-Marseille Université Access content directly
Journal Articles Lancet Oncology Year : 2016

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

Olivier Mir
Antoine Italiano
Jean-Yves Blay
Christophe Perrin
  • Function : Author
Isabelle Ray-Coquard
Olivier Collard
  • Function : Author
Laurence Bozec
  • Function : Author
Didier Cupissol
  • Function : Author
Esma Saada-Bouzid
  • Function : Author
Christine Lemaignan
  • Function : Author
Wolfgang Eisterer
  • Function : Author
Nicolas Isambert
  • Function : Author
  • PersonId : 940320
Loïc Chaigneau
  • Function : Author
Axel Le Cesne
  • Function : Author
Nicolas Penel

Domains

Cancer
No file

Dates and versions

hal-03623726 , version 1 (29-03-2022)

Identifiers

Cite

Olivier Mir, Thomas Brodowicz, Antoine Italiano, Jennifer Wallet, Jean-Yves Blay, et al.. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, 2016, 17 (12), pp.1732-1742. ⟨10.1016/s1470-2045(16)30507-1⟩. ⟨hal-03623726⟩
28 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More